Millions May Be Getting The Wrong Cholesterol Test

New research published in JAMA indicates that measuring apolipoprotein B (apoB) may provide a more accurate assessment of heart attack and stroke risk than the traditional LDL cholesterol test. The study suggests that widespread adoption of apoB testing could lead to better targeting of cholesterol-lowering treatments and improved health outcomes for millions of Americans.

The study, conducted by Northwestern Medicine, analyzed data from a computer simulation of 250,000 U.S. adults eligible for statin therapy but without existing cardiovascular disease. Researchers compared three strategies: LDL cholesterol, non-HDL cholesterol, and apoB levels, to determine which best predicted cardiovascular events and was most cost-effective. Results showed that using apoB to guide treatment consistently prevented more heart attacks and strokes than the other two methods, with benefits achieved at a favorable cost to healthcare payers.

Lead author Ciaran Kohli-Lynch explained that apoB measures the total number of harmful particles in the blood, providing a more direct indicator of cardiovascular risk than LDL or non-HDL cholesterol levels. Despite this, apoB testing is not yet routine, partly due to the need for an additional blood test, which increases costs and inconvenience. The study argues that the health benefits justify the extra expense, especially as new medications and guidelines promote earlier and more aggressive treatment for at-risk populations.

Implications of Using ApoB for Heart Disease Prevention

This research could influence future clinical guidelines by encouraging the adoption of apoB testing, potentially leading to more precise identification of individuals at risk for heart attacks and strokes. As the American Heart Association and other organizations recommend earlier intervention, accurate testing becomes increasingly vital. Widespread use of apoB could reduce cardiovascular events, improve patient outcomes, and lower long-term healthcare costs by avoiding unnecessary or ineffective treatments.

Increasing Focus on Accurate Cholesterol Risk Assessment

Currently, most doctors rely on LDL and non-HDL cholesterol tests to determine when to begin or escalate cholesterol-lowering therapy. However, these tests do not fully capture an individual’s risk, as they do not directly measure harmful particles that contribute to plaque buildup. The emerging evidence supporting apoB’s superior predictive ability has yet to translate into routine practice, partly due to cost and testing logistics. The study’s findings come amid updated guidelines advocating for earlier and more intensive lipid management, heightening the need for precise risk assessment tools.

“Our findings suggest that apoB testing to guide treatment would prevent more heart attacks and strokes than current practices, and at a cost that is justified by the health benefits.”

— an anonymous researcher

Uncertainties About Clinical Implementation and Cost

It is not yet clear how quickly clinical guidelines will incorporate apoB testing as standard practice. The long-term cost-effectiveness in real-world settings, beyond the computer simulation, remains to be confirmed. Additionally, how insurance coverage and patient acceptance will influence adoption is still uncertain.

Next Steps for Research and Clinical Practice

Further real-world studies are needed to validate these findings and assess the impact of apoB testing in diverse populations. Medical organizations may consider updating guidelines to recommend apoB measurement, and healthcare providers will need to evaluate logistical and cost considerations. Policymakers and insurers will also play a role in facilitating wider access to this testing method.

Key Questions

Why is apoB testing considered more effective than LDL testing?

ApoB measures the total number of harmful cholesterol particles in the blood, providing a more direct assessment of cardiovascular risk than LDL cholesterol levels, which only measure the amount of cholesterol carried by particles.

Will this change current cholesterol testing practices?

It is uncertain how quickly clinical guidelines will incorporate apoB testing. Adoption depends on further validation, cost considerations, and healthcare policy decisions.

Are there any barriers to using apoB testing routinely?

Yes, the need for an additional blood test increases costs and patient inconvenience, which currently limit widespread use despite the evidence of its benefits.

How might this impact patients at risk for heart disease?

If adopted, apoB testing could lead to more personalized and effective treatment plans, potentially reducing the incidence of heart attacks and strokes among high-risk individuals.

Source: rss